Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease

American Journal of Physiology - Renal Physiology

Volumn 297, Issue 6, 2009, Pages

  Wu, Ming ^a   Arcaro, Alexandre ^b   Varga, Zsuzsanna ^c   Vogetseder, Alexander ^a   Le Hir, Michel ^a   Wüthrich, Rudolf P ^a,c   Serra, Andreas L ^a,c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

4E BP1; Han:SPRD; S6K

Indexed keywords

EVEROLIMUS; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG PULSE THERAPY; ENZYME ACTIVITY; KIDNEY HYPERTROPHY; KIDNEY PARENCHYMA; KIDNEY POLYCYSTIC DISEASE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT;

EID: 71449093471     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00430.2009     Document Type: Article

References (35)

1. Berthier CC, Wahl PR, Le Hir M, Marti HP, Wagner U, Rehrauer H, Wuthrich RP, Serra AL. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 23: 880-889, 2008. (Pubitemid 351767564)
2. Bikopoulos G, Ceddia RB, Sweeney G, Hilliker AJ. Insulin reduces apoptosis and increases DNA synthesis and cell size via distinct signalling pathways in Drosophila Kc cells. Cell Prolif 37: 307-316, 2004. (Pubitemid 38951776)
3. Brugarolas J, Kaelin WG Jr. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6: 7-10, 2004. (Pubitemid 38903157)
4. Chang MY, Parker E, Ibrahim S, Shortland JR, Nahas ME, Haylor JL, Ong AC. Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models. Nephrol Dial Transplant 21: 2078-2084, 2006. (Pubitemid 44295032)
5. Chen JK, Chen J, Neilson EG, Harris RC. Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol 16: 1384-1391, 2005. (Pubitemid 41716522)
6. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 105: 17414-17419, 2008.
7. Foster DA. Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Biochim Biophys Acta 1791: 949-955, 2009.
8. Franz KA, Reubi FC. Rate of functional deterioration in polycystic kidney disease. Kidney Int 23: 526-529, 1983.
9. Fumarola C, La Monica S, Alfieri RR, Borra E, Guidotti GG. Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis. Cell Death Differ 12: 1344-1357, 2005. (Pubitemid 41486104)
10. Gattone VH 2nd, Sinders RM, Hornberger TA, Robling AG. Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis. Kidney Int 76: 178-182, 2009.
11. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 15: 807-826, 2001.
12. Gretz N, Kranzlin B, Pey R, Schieren G, Bach J, Obermuller N, Ceccherini I, Kloting I, Rohmeiss P, Bachmann S, Hafner M. Rat models of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 11, Suppl 6: 46-51, 1996. (Pubitemid 27055659)
13. Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando) 22: 125-130, 2008.
14. Liu E, Morimoto M, Kitajima S, Koike T, Yu Y, Shiiki H, Nagata M, Watanabe T, Fan J. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol 18: 2094-2104, 2007. (Pubitemid 47041075)
15. Masoumi A, Reed-Gitomer B, Kelleher C, Schrier RW. Potential pharmacological interventions in polycystic kidney disease. Drugs 67: 2495-2510, 2007. (Pubitemid 350159164)
16. Mathieu O, Cruz-Orive LM, Hoppeler H, Weibel ER. Measuring error and sampling variation in stereology: comparison of the efficiency of various methods for planar image analysis. J Microsc 121: 75-88, 1981.
17. Nagai K, Matsubara T, Mima A, Sumi E, Kanamori H, Iehara N, Fukatsu A, Yanagita M, Nakano T, Ishimoto Y, Kita T, Doi T, Arai H. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int 68: 552-561, 2005. (Pubitemid 43323110)
18. Obermuller N, Kranzlin B, Blum WF, Gretz N, Witzgall R. An endocytosis defect as a possible cause of proteinuria in polycystic kidney disease. Am J Physiol Renal Physiol 280: F244-F253, 2001. (Pubitemid 32473279)
19. O'Donnell A, Faivre S, Burris HA, 3rd Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26: 1588-1595, 2008.
20. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508, 2006. (Pubitemid 43259931)
21. Ponticelli C. The pleiotropic effects of mTor inhibitors. J Nephrol 17: 762-768, 2004.
22. Rangan GK, Coombes JD. Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis. Nephrol Dial Transplant 22: 2175-2182, 2007. (Pubitemid 47244694)
23. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729-734, 2006.
24. Serra AL, Kistler AD, Poster D, Struker M, Wuthrich RP, Weishaupt D, Tschirch F. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrol 8: 13, 2007. (Pubitemid 350045997)
25. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 103: 5466-5471, 2006.
26. Tanner GA, Tielker MA, Connors BA, Phillips CL, Tanner JA, Evan AP. Atubular glomeruli in a rat model of polycystic kidney disease. Kidney Int 62: 1947-1957, 2002.
27. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16: 46-51, 2005. (Pubitemid 43073155)
28. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 21: 598-604, 2006. (Pubitemid 43372904)
29. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-1940, 2007.
30. Weimbs T. Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair? Cell Cycle 5: 2425-2429, 2006. (Pubitemid 44785815)
31. Wilson PD. Polycystic kidney disease. N Engl J Med 350: 151-164, 2004.
32. Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, Serra AL. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 30: 253-259, 2007. (Pubitemid 47076223)
33. Zafar I, Belibi FA, He Z, Edelstein CL. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant 24: 2349-2353, 2009.
34. Zeier M, Fehrenbach P, Geberth S, Mohring K, Waldherr R, Ritz E. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 42: 1259-1265, 1992.
35. Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, Kwiatkowski DJ. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 117: 730-738, 2007. (Pubitemid 46348531)